Japan Tissue Engineering reports wider FY2026 parent loss

5 articles · Updated · MarketWatch · May 1

For the year ended 31 March, net loss widened to Y734 million from Y255 million as revenue fell to Y2.18 billion from Y2.46 billion.
Operating loss deepened to Y549 million from Y238 million, while pretax loss widened to Y537 million from Y234 million.
Per-share loss increased to Y18.09 from Y6.29, and the company reported no interim or year-end dividend under Japanese accounting standards.

Amidst a market boom, why is Japan’s tissue engineering pioneer collapsing financially?

Are new iPS cell therapies making Japan's original regenerative medicine pioneers obsolete?